SENSEI BIOTHERAPEUTICS INC. - COMMON STOCK

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

01 Nov 2023 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

25 Oct 2023 08:05:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

23 Oct 2023 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®

27 Sep 2023 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

21 Sep 2023 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

13 Sep 2023 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

30 Aug 2023 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

03 Aug 2023 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in Canaccord Genuity’s 43rd Annual Growth Conference

02 Aug 2023 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101’s Potential as a Transformative Treatment Option for Patients with Solid Tumors”

13 Jun 2023 07:32:15 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors

01 Jun 2023 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

31 May 2023 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

09 May 2023 06:30:01 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

20 Apr 2023 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023

18 Apr 2023 15:05:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference

13 Apr 2023 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in Cantor Fitzgerald’s Future of Oncology Virtual Symposium

30 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights

28 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody

21 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023

14 Mar 2023 15:35:00 By Nasdaq GlobeNewswire